📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-12 18:35
0 analysed today
FollowTelegram
0
Today
149,939
All-time analysed
42,983
Positive
6,669
Negative
91,579
Neutral
8,640
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
3 announcements match the current filters (relevance ≥ 5).
GKB Ophthalmics Q1 Standalone Revenue at ₹6.40 Cr; Net Loss Narrows to ₹0.50 Cr
GKB Ophthalmics reported a 26.5% YoY decline in standalone revenue to ₹6.40 Cr for Q1 FY27. However, the standalone net loss narrowed significantly to ₹0.50 Cr from a loss of ₹2.14 Cr in the same quarter last year, aided by a reduction in total expenses from ₹10.97 Cr to ₹7.61 Cr. A key development is the receipt of ₹11.70 Cr from the voluntary winding up of its subsidiary GSV Ophthalmics, which represents approximately 15.6% of the company's current market capitalization. The company also completed the closure of its step-down subsidiary, Prime Ophthalmics Products PTY Ltd, resulting in a ₹43.50 lakh write-off.
Confidence: HIGH
What changedThe company reported its Q1 FY27 financial results, finalized the closure of a non-performing step-down subsidiary, and confirmed the receipt of significant cash from a voluntary winding up process.
Why it mattersThe narrowing of losses is a positive sign of cost control, and the substantial cash recovery from the subsidiary winding up significantly strengthens the balance sheet of this micro-cap company.
Standalone Revenue (Q1 FY27): ₹6.40 CrStandalone Net Loss (Q1 FY27): ₹0.50 CrCash from GSV Winding Up: ₹11.70 CrGSV Cash vs Market Cap: ~15.6%Subsidiary Write-off: ₹43.50 lakhs
📅 Short termThe stock may see mixed reactions; the revenue drop is concerning, but the narrowed loss and significant cash recovery from the subsidiary provide a liquidity cushion.
📈 Long termThe company is streamlining its corporate structure by closing non-performing units. Long-term value depends on stabilizing the core lens business and improving operating margins from the current 5.7%.
⚠ Risk flags
- Significant YoY revenue decline
- Continued standalone losses
- Write-offs from subsidiary closures
Key Highlights
Standalone revenue for Q1 FY27 stood at ₹6.40 Cr, down from ₹8.71 Cr in Q1 FY26.
Standalone net loss narrowed to ₹0.50 Cr compared to a loss of ₹2.14 Cr in the previous year's quarter.
Received ₹11.70 Cr cash inflow from the voluntary winding up of material subsidiary GSV Ophthalmics.
Wrote off ₹43.50 lakhs following the closure of step-down subsidiary Prime Ophthalmics Products PTY Ltd on July 02, 2026.
Total standalone expenses decreased by 30.6% YoY to ₹7.61 Cr.
👀 What to Watch
Investors should monitor how the company utilizes the ₹11.70 Cr cash inflow from the subsidiary winding up and whether the core manufacturing business can reverse the current revenue decline.
GKB Ophthalmics reports Q1 results; challenges ₹8.82 Cr legal demand
GKB Ophthalmics reported a standalone revenue of ₹6.40 Cr for Q1 FY27, a 27.6% decline from ₹8.84 Cr in the same quarter last year. The company is currently contesting a significant legal demand of ₹8.82 Cr from the Labour Commissioner, which represents approximately 16.6% of its net worth (₹53 Cr). Additionally, the company has closed its non-performing Australian step-down subsidiary, writing off an investment of AED 1,69,325.58. While standalone net losses narrowed to ₹0.67 Cr from ₹1.88 Cr YoY, the legal dispute remains a primary concern for liquidity.
Confidence: HIGH
What changedThe company has initiated legal action against a major recovery notice and completed the closure of a non-performing international subsidiary.
Why it mattersThe legal demand of ₹8.82 Cr is highly material, exceeding the company's total TTM PAT of ₹3 Cr and representing a significant portion of its market cap. The subsidiary closure is a strategic move to stop financial leakage from underperforming assets.
Legal Demand: ₹8.82 CrDemand vs Net Worth: 16.6%Standalone Revenue (Q1 FY27): ₹6.40 CrInvestment Write-off: AED 1,69,325.58Standalone Net Loss (Q1 FY27): ₹0.67 Cr
📅 Short termThe stock may face pressure or volatility leading up to the August 19 court hearing regarding the ₹8.82 Cr demand.
📈 Long termThe restructuring of international subsidiaries could streamline operations, but the company needs to demonstrate consistent revenue growth and profitability to re-rate.
⚠ Risk flags
- Significant legal liability (₹8.82 Cr)
- Declining standalone revenue
- History of quarterly losses
Key Highlights
Standalone revenue for Q1 FY27 decreased to ₹6.40 Cr from ₹8.84 Cr in Q1 FY26.
Legal demand of ₹8.82 Cr from the Mamlatdar of Bardez Taluka challenged in High Court (Hearing: Aug 19, 2026).
Write-off of AED 1,69,325.58 following the closure of Prime Ophthalmics Products PTY Limited on July 02, 2026.
Standalone net loss narrowed to ₹0.67 Cr for the quarter ended June 30, 2026, compared to ₹1.88 Cr loss YoY.
Prescription Optical Products LLC (POPL) restructured into a Wholly Owned Subsidiary of the Sharjah-based FZE unit.
👀 What to Watch
Investors should closely monitor the outcome of the High Court hearing on August 19, 2026, as an adverse ruling on the ₹8.82 Cr demand would significantly impact the company's cash position. Track consolidated results to see if the closure of the loss-making Australian unit improves overall margins.
₹8.82 Cr Demand Notice Received by GKB Ophthalmics in Ongoing Labour Dispute
GKB Ophthalmics has received a formal 'Notice of Demand' for ₹8.82 crore from the Mamlatdar of Bardez Taluka, Goa, following a long-standing labour dispute (Case No. 32/09). The notice, received on July 13, 2026, mandates the recovery of dues within a strict 10-day period. This stems from an Industrial Tribunal award dated May 25, 2021, and a subsequent recovery order by the Labour Commissioner in September 2025. The company intends to challenge this demand by filing a writ petition in the High Court of Bombay.
Confidence: HIGH
What changedA long-standing legal dispute has escalated from a tribunal award to an active recovery demand by local authorities with a specific 10-day deadline.
Why it mattersA potential cash outflow of ₹8.82 crore could be material for a company of this size, potentially impacting liquidity and working capital if legal relief is not granted.
Recovery Amount: ₹8,82,00,856Payment Deadline: 10 daysNotice Receipt Date: July 13, 2026Original Award Date: May 25, 2021
📅 Short termThe stock may face downward pressure due to the immediate threat of a ₹8.82 crore recovery and the legal uncertainty surrounding the 10-day deadline.
📈 Long termThe outcome of the High Court petition will determine if this is a one-time hit or if there are structural increases in labour-related costs for the company.
⚠ Risk flags
- Liquidity risk due to immediate demand for ₹8.82 cr
- Litigation risk
- Execution risk in obtaining timely legal stay
Key Highlights
Demand notice for ₹8,82,00,856 received on July 13, 2026, at 5:00 PM.
Payment or recovery of the full amount is required within a 10-day window.
The dispute originates from an Industrial Tribunal Award passed on May 25, 2021.
The Labour Commissioner had previously passed the recovery order on September 4, 2025.
Company is seeking legal relief via a writ petition in the High Court of Bombay.
👀 What to Watch
Investors should closely monitor whether the company successfully obtains a stay order from the High Court before the 10-day payment deadline expires.
